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transcriptional Upregulation of 
NLRC5 by Radiation Drives STING- 
and Interferon-Independent MHC-I 
Expression on Cancer Cells and T 
Cell Cytotoxicity
Lauren K. Zebertavage1,2, Alejandro Alice1, Marka R. crittenden1,3 & Michael J. Gough1 ✉
Radiation therapy has been shown to enhance the efficacy of various T cell-targeted immunotherapies 
that improve antigen-specific T cell expansion, T regulatory cell depletion, or effector T cell function. 
Additionally, radiation therapy has been proposed as a means to recruit T cells to the treatment site 
and modulate cancer cells as effector T cell targets. The significance of these features remains unclear. 
We set out to determine, in checkpoint inhibitor resistant models, which components of radiation 
are primarily responsible for overcoming this resistance. In order to model the vaccination effect of 
radiation, we used a Listeria monocytogenes based vaccine to generate a large population of tumor 
antigen specific T cells but found that the presence of cells with cytotoxic capacity was unable to 
replicate the efficacy of radiation with combination checkpoint blockade. Instead, we demonstrated 
that a major role of radiation was to increase the susceptibility of surviving cancer cells to CD8+ T cell-
mediated control through enhanced MHC-I expression. We observed a novel mechanism of genetic 
induction of MHC-I in cancer cells through upregulation of the MHC-I transactivator NLRC5. These 
data support the critical role of local modulation of tumors by radiation to improve tumor control with 
combination immunotherapy.
It is clear that radiation therapy (radiotherapy, RT) has significant immune modulatory effects and is capable of 
unleashing potent anti-tumor CD8+ T cell responses1–6. The ability of radiotherapy to enhance adaptive immune 
responses has further been highlighted by the ability of radiation to enhance the therapeutic efficacy of PD-1/
PD-L1 checkpoint blockade in preclinical models6–10. While interest in abscopal effects, or those observed out-
side of the field of irradiation, have increased in part due to the observation that radiation can act as an in situ 
vaccine10,11, recent studies by our group and others have determined that combination radiation and checkpoint 
blockade therapy requires pre-existing T cell responses to control tumors1,12. Given the strong interest in using 
existing therapies such as radiation to enhance αPD-1/αPD-L1 responses in human cancers, it is critical to 
understand the mechanisms by which RT is improving outcomes to better inform treatment of patients13,14.
In this study, we aimed to determine the mechanisms by which radiation overcomes αPD-L1 therapeutic 
resistance using murine models of pancreatic cancer expressing model antigens. Here, we were able to dissect 
out the role of vaccination effects, T cell trafficking, and cancer cell phenotype modifications and we found that 
while radiation was able to boost tumor-specific CD8+ T cell responses, vaccine effects were not sufficient to 
recapitulate the efficacy of radiotherapy with checkpoint blockade. We found that in our model radiation did 
not improve trafficking or retention of tumor-reactive CD8+ T cells to tumors. However, experiments in vitro 
and in vivo indicated that alterations in cancer cell phenotypes, particularly by upregulation of MHC-I surface 
expression, are sufficient to enhance control of tumors by antigen-specific CD8+ T cells. Finally, we observed a 
novel mechanism of transcriptional regulation of MHC-I expression on tumor cells by expression of the MHC-I 
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transactivator NLRC5 (NOD-like receptor C5) and found that expression of NLRC5 by cancer cells enhanced 
cytotoxic cytokine production by CD8+ T cells.
Results
In order to determine if the generation of tumor-specific CD8+ T cells by tumor irradiation was sufficient to 
induce overcome αPD-L1 checkpoint blockade therapeutic resistance, we used the murine Panc02 model of pan-
creatic adenocarcinoma15 expressing a fusion of eGFP and the model antigen SIYRYYGL (SIY) and purified for 
high expression of antigen (Panc02SIY100)16. Subcutaneous Panc02SIY100 tumors in C57BL/6 mice are resistant 
to αPD-L1 checkpoint blockade (median survival NT 62d vs. anti-PD-L1 73d p = 0.1771), have a low cure rate 
with a single dose of RT (12 Gy) (median survival NTvs.RT 80d p = 0.0108), and a cure rate that is markedly 
enhanced by the combination of RT and αPD-L1 checkpoint blockade (Fig. 1A). In this model there is not a ther-
apeutic synergy since while the combination of RT and anti-PD-L1 increase cure rates they are not significantly 
different by Logrank test from RT alone (median survival RT + anti-PD-L1 undefined vs. anti-PD-L1 p = 0.0306; 
vs. RT p = 0.2460). However, it is important that combination is not effective in mice tolerant to the model antigen 
SIY (PDX-SIY) (Fig. 1A–C), indicating that effective tumor cure induced by RT + anti-PD-L1 to Panc02SIY100 
is entirely dependent on CD8+ T cells responsive to the model antigen.
To test whether a large number of model antigen-reactive CD8+ T cells was sufficient to replicate the efficacy 
of RT in Panc02SIY100, we used a live-attenuated Listeria monocytogenes vaccine expressing SIY (LmSIY) to gen-
erate large numbers of tumor-reactive CD8+ T cells. While radiation therapy was able to significantly increase 
the number of SIY-specific T cells in circulation (p < 0.01), LmSIY vaccination was more than an order of mag-
nitude more effective at generating SIY-specific T cells (Fig. 1D). Despite these increases in SIY-reactive CD8+ 
T cells compared to radiation alone, vaccination did not significantly improve survival or slow tumor growth 
either alone or in combination with anti-PD-L1 (Fig. 1D,E). Similarly, in an immune competent animal, adding 
vaccination with LmSIY to RT did not improve tumor control in the absence of anti-PD-L1 (Supplemental Fig. 1). 
These results indicate that potent anti-cancer vaccination strategies cannot replicate the efficacy of RT combined 
with αPD-L1, suggesting additional radiation-induced changes other than the induction of tumor-specific CD8+ 
T cells are required to control tumors.
We designed a series of experiments to test the trafficking and functionality of Listeria-induced CD8+ T cells 
to determine whether this could account for the inferior outcomes we observed with LmSIY and αPD-L1. To 
determine whether the failure of Listeria-induced CD8+ T cells to cure was due to failure to traffic to tumors, we 
examined tumors post-RT by immunohistochemistry (IHC). T cells were found in greater numbers following 
vaccination when compared to untreated controls and formed distinct clusters at peak infiltration, suggestive of 
in situ activation (Fig. 2A). Notably, T cell infiltration following tumor irradiation detected by IHC was compa-
rable to numbers following vaccination with LmSIY (data not shown). In order to test the in vivo functionality 
of Listeria-induced CD8+ T cells, we performed an in vivo CTL assay, where target or irrelevant peptide-pulsed 
congenic splenocytes were co-transferred into vaccinated animals. As expected, LmSIY vaccination selectively 
depleted SIY-pulsed cells, and the control LmOva vaccination selectively depleted SIINFEKL-pulsed cells 
(Fig. 2B), indicating that Listeria vaccines formed functional antigen-specific CD8+ T cell cytotoxic immunity 
for both LmSIY and control LmOva. To test whether vaccine-generated T cells recognized antigen within tum-
ors, transgenic Nur77GFP reporter mice17 were implanted with SIY-expressing tumors and either vaccinated or 
treated with radiation therapy (Fig. 2Ci). T cells from Nur77GFP mice become fluorescent following ligation of 
the T cell receptor with its cognate antigen and lose signal over a narrow window of time (data not shown). 
Tumors harvested from Nur77GFP mice following LmSIY or LmOva vaccination resulted in the accumulation of 
SIY-specific or SIINFEKL-specific T cells in the tumor, respectively (Fig. 2Cii). As expected, SIY-specific T cells 
actively recognized antigen in the tumor as determined by expression of Nur77-GFP, while SIINFEKL-specific T 
cells did not (Fig. 2Ciii). Importantly, Nur77-GFP expression in SIY-specific T cells was not significantly different 
across treatments (Fig. 2Civ), indicating that T cells generated by vaccination recognize tumor antigen at simi-
lar rates to radiation-generated and existing tumor-infiltrating SIY-specific T cell populations. To test whether 
Listeria-induced CD8+ T cells were capable of controlling antigen-matched cancer cells, CD8+ T cells were har-
vested from non-tumor-bearing animals vaccinated with LmSIY or LmOva and cocultured with Panc02SIY100. 
Cancer cell growth was monitored microscopically in vitro over time with green fluorescence as a proxy for 
cancer cell confluence (Fig. 2Di). Significantly, LmSIY-induced splenocytes were not capable of suppressing 
Panc02SIY100 growth in vitro unless cancer cells were pretreated with interferon gamma (IFNγ) prior to cocul-
ture (Fig. 2Dii). Taken together, these results indicate that LmSIY-induced CD8+ T cells are cytotoxic, effectively 
traffic to SIY-expressing tumors and recognize antigen in the tumor; however, Panc02SIY100 cells are intrinsically 
resistant to killing by antigen-specific CD8+ T cells in the absence of phenotypic modifications induced here by 
IFNγ.
These experiments led us to consider phenotypic modifications induced by IFNγ stimulation that are shared 
by irradiation, among which increased cell surface presentation of MHC-I (Fig. 3A) is of particular interest due 
to the essential role of antigen presentation in CD8+ T cell function. The pancreatic adenocarcinoma cell lines 
have very low basal MHC-I expression, but are responsive to IFNγ stimulation (Supplementary Fig. 2). RT is also 
a known modulator of MHC-I expression and similarly, we observed dose-dependent increases in MHC-I on 
tumor cell surfaces by RT (Fig. 3B). Similar to IFNγ pretreatment, we observed that irradiating tumor cells was 
sufficient to induce modifications within the cancer cells to allow control in vitro by tumor antigen-specific CD8+ 
T cells (Fig. 3C). IFNγ was more effective than radiation in inducing MHCI on the cancer cells (Fig. 3B), and we 
were not able to further increase the dose of radiation to attempt to amplify MHCI induction due to its cytotoxic 
effect on the cancer cells. Moreover, IFNγ was able to maximally induce MHCI on cancer cells and did not permit 
an additive effect from combining RT and IFNγ treatment in vitro. Based on these data, we hypothesized that 
irradiation improves cancer cell susceptibility to CD8+ T cell mediated killing by augmenting MHC-I expression.
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The mechanisms by which radiation induces MHC-I expression in cancer cells is not completely understood. 
Cancer cells are not thought to be sources of IFNγ, but MHC-I expression can be directly regulated by type I 
interferon (IFN-I) signaling and studies have indicated that host responses to IFN-I through the receptor IFNAR 
are essential to the anti-cancer CD8+ T cell response driven by radiotherapy18. Recently, a series of publications 
indicated that IFN-I secretion following RT might be initiated by cancer cells themselves responding to cytosolic 
DNA fragments activating cGAS/STING, a process negatively regulated by activation of the DNA exonuclease 
Trex119–21. To test the role of cancer cell intrinsic STING signaling in MHC-I induction in cancer cells, cancer cell 
lysate was immunoblotted and we observed that, contrary to the parental cancer cell line Panc02, Panc02SIY100 
expresses very low levels of STING protein (Fig. 4A). To determine whether this was unique to Panc02SIY100, 
we also tested pancreatic cancer cells derived from Pdx-Cre+/−Kras(G12D)+/−Trp53(R172H)+/−R26LSL-LSIY/+ mice, 
Figure 1. Model antigen-reactive CD8+ T cells are necessary but not sufficient to induce regression of 
Panc02SIY100 tumors. (A) (i) treatment schema, (ii) overall survival of treatment groups: no treatment (NT), 
αPD-L1 alone (αPD-L1), radiation alone (RT) and combination αPD-L1 and radiation (αPD-L1 + RT). (B) 
SIYRYYGL-pentamer (pSIY)- binding CD8+ T cells quantified from blood at day 7 following Panc02SIY 
tumor implantation in wild-type (WT) or SIYRYYGL-tolerant (PDX-SIY) mice. (c) tumor growth from mice 
implanted with Panc02SIY100 tumors and treated as in (A). (D) (i) treatment schema, (ii) pSIY-binding CD8+ 
T cells quantified from blood a day 7 following LmSIY vaccination or tumor irradiation. (E) (i) average tumor 
growth from mice implanted with Panc02SIY100 tumors and treated with αPD-L1 and RT as described in A or 
LmSIY at day 14 (ii) overall survival of treatment groups. Key: *p < 0.05; **p < 0.01; ****p < 0.0001; ns = not 
significant.
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Figure 2. Listeria-induced CD8+ T cells are cytotoxic in vivo but are poorly effective at controlling tumor growth 
in the absence of interferon pretreatment. (A) (i) immunohistochemistry of CD3 infiltration from tumor sections 
from mice not treated (NT) or treated with LmSIY at indicated times following tumor challenge (d6, d13, d16 and 
d19), (ii) quantification of CD3+ infiltration by immunohistochemistry. (B) (i) representative dot plot of splenocytes, 
(ii) representative histograms of CFSE-labeled CD45.1+ cells from unvaccinated, LmOva vaccinated or LmSIY 
vaccinated mice, (iii) quantification of percent specific lysis where NT and LmSIY reflects lysis of SIYRYYGL-pulsed 
cells and LmOva reflects lysis of SIINFEKL-pulsed cells. (C) (i) treatment schema, (ii) representative dot plots of 
tumor-infiltrating CD8+ T cells, (iii) quantification of MHC-multimer binding of tumor-infiltrating CD8+ T cells 
where tOva represents SIINFEKL tetramer binding cells and pSIY represents SIYRYYGL pentamer binding cells, (iv) 
quantification of Nur77-GFP+ cells of tumor-infiltrating CD8+ T cells where tOva represents SIINFEKL tetramer 
binding cells and pSIY represents SIYRYYGL pentamer binding cells. (D) (i) representative Incucyte images of 
Panc02SIY100 cells untreated or pretreated for 24 hours with IFNγ and cocultured with splenocytes from LmSIY-
vaccinated mice, (ii) growth chart of Panc02SIY100 cancer cells following coculture with splenocytes from LmOva- or 
LmSIY- vaccinated animals. Key: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns = not significant.
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PK5L19401 and found similarly low STING expression. We further observed by treating cancer cells lines in vitro 
with RT or the endogenous STING ligand 2′,3′-cGAMP that cell lines with low expression of STING protein were 
still able to upregulate MHC class I (MHC-I) in response to irradiation but not to STING ligand. In contrast, 
Panc02 was able to upregulate MHC-I in response to both treatment with 2′,3′-cGAMP and radiation (Fig. 4B). 
These results indicate that STING signaling in cancer cells is not required for RT-induced MHC-I modulation.
Previous work has indicated that cancer cell-derived IFN-I secreted following irradiation induces MHC-I 
upregulation on cancer cells22. To test whether alternate inflammatory sensors drive MHC-I upregulation via 
endogenous IFN-I production, we knocked out the IFN-I receptor (IFNAR) in cancer cell lines. IFNAR is a 
heterodimeric receptor consisting of two subunits, IFNAR1 and one of several distinct isoforms of IFNAR223. 
Mutation of the IFNAR1 gene by CRISPR/Cas9 editing removed detectable IFNAR1 expression on the cell sur-
face (Supplementary Fig. 3) and rendered cancer cells insensitive to exogenous IFNβ stimulation (Fig. 4B). The 
pancreatic adenocarcinoma cell lines exhibited poor basal expression of STAT1, though they upregulated STAT1 
following IFNβ treatment in wild type, but not IFNAR1ko cell lines (Supplementary Fig. 4). The addition of RT to 
IFNβ did not alter the response to IFNβ, and RT was not able to upregulate STAT1 without IFNβ, consistent with 
a lack of STING pathway activation (Supplementary Fig. 4). As expected, the response to IFNγ was unchanged in 
IFNAR1ko cell lines. Significantly, IFNAR1ko cell lines that are unable to upregulate MHC-I in response to exoge-
nous IFNβ stimulation retain their ability to upregulate MHC-I in response to RT (Fig. 4C). To determine whether 
loss of cancer cell IFN-I signaling affected RT efficacy, we treated Panc02SIY100-IFNAR1ko tumors with thera-
peutic doses of RT and αPD-L1 in vivo and found similar combined efficacy (Fig. 4D). Notably, overall survival 
in the combination therapy group was higher in mice bearing parental tumors than Panc02SIY100-IFNAR1ko, 
likely due to the more aggressive growth rate of cancer cells unable to respond to type I IFN. Tumors formed from 
cancer cells lacking IFNAR were analyzed for infiltrating immune cells by flow cytometry, and although these 
tumors were generally larger, there was not significant difference in the baseline number of the major immune cell 
populations, or SIY-specific CD8 T cells (Supplementary Fig. 5). Radiation therapy also resulted in similar effects 
on these immune cells following treatment of wild-type or IFNAR1ko tumors (Supplementary Fig. 5), suggesting 
that the responsiveness of cancer cells to type I IFN does not greatly impact the tumor immune environment. 
Together, these data demonstrate that the endogenous cancer cell response to IFN-I is not required for upregula-
tion of MHC-I by radiation or tumor control by radiation and αPD-L1 blockade.
A key genetic driver of MHC-I expression is the MHC Class I Transactivator (CITA, or NLRC5)24–26, a 
reported target of immune evasion in human cancers27. To determine whether this was true for human pancreatic 
cancers, we examined RNAseq gene expression data from 35 human patients with resectable pancreatic adeno-
carcinoma (Table 1) and found that NLRC5 expression tightly correlated with expression of MHC-I heavy chain 
HLA molecules, light chain β2 microglobulin (B2M) and TAP1 expression (Fig. 5A). This was also true when 
examining mRNA expression in patients analyzed as part of the TCGA Pancreatic Adenocarcinoma PanCancer 
Atlas28 as a validation cohort using cBioportal29,30 (Supplementary Table 1). In these patients, NLRC5 was highly 
correlated with HLA-B expression along with other key components of the antigen processing and presentation 
pathway. In our murine pancreatic cancer cell lines, we found that the parental cell line Panc02 had much higher 
Figure 3. Radiation increases MHC-I expression and improves susceptibility of cancer cells to control by 
antigen-specific CD8+ T cells. (A) Quantification of MHC-I expression by flow cytometry of pancreatic cancer 
cell lines with and without 72 hours of IFNγ stimulation. (B) Representative histogram of MHC-I expression of 
Panc02SIY100 cancer cells 72 hours following irradiation at indicated doses. (C) growth charts of Panc02SIY100 
cancer cells following pretreatment with in vitro irradiation or IFNγ and during coculture with in vitro activated 
OT-I or 2 C T cells. Key: *p < 0.05; **p < 0.01; ****p < 0.0001; ns = not significant.
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expression of NLRC5 than the Panc02SIY100 subclone, correlating with its much higher basal expression of 
MHC-I (Fig. 5B). Baseline expression of NLRC5 was very low, close to the limit of detection (Supplementary 
Fig. 6), but we found that irradiation of Panc02SIY100 significantly increased transcription of NLRC5 and related 
genes B2M and TAP1 in a dose-dependent manner (Fig. 5C). NLRC5 is also upregulated following radiation 
therapy in cells lacking IFNAR1 (Supplementary Fig. 7), indicating that this mechanism is independent of IFN 
signaling in irradiated cells. Therefore, we believe that upregulation of NLRC5 represents a potentially novel 
mechanism of MHC-I regulation induced by radiation.
To determine whether constitutive NLRC5 expression was sufficient to restore MHC-I in Panc02SIY100, cells 
were transfected with a plasmid harboring the sequence for NLRC5 under the constitutive promoter eukary-
otic translation elongation factor 1 alpha (EF-1α) and transfected cells were found to have very high basal lev-
els of MHC-I expression (Fig. 5D). To determine the functional consequences of MHC-I induction by NLRC5 
expression in cancer cells, Panc02SIY100-NLRC5 was cocultured with 2 C T cells from Nur77GFP mice. Equivalent 
Figure 4. Type I interferon (IFN-I) responsiveness does not dictate MHC-I expression or clearance of 
Panc02SIY100 tumors. (A) Western blot of STING and IRF3 expression in pancreatic cell lines with GAPDH 
loading control. (B) flow cytometric MFI of MHC-I expression of pancreatic cell lines 72 hours after 
stimulation with 2′3′-cGAMP or irradiation in vitro. (C) quantification of MHC-I expression of pancreatic 
cell lines following 72 hours IFNβ stimulation. (D) quantification of MHC-I expression of pancreatic cell lines 
72 hours following irradiation at indicated doses. (E) tumor growth of mice implanted with Panc02SIY100 
or Panc02SIY100-IFNAR1ko tumors and treated as in 1A. Key: *p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001; ns = not significant.
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proportions of 2 C T cells recognized tumor antigen when cocultured with MHC-Ihi Panc02SIY100-NLRC5 com-
pared to MHC-Ilo Panc02SIY100 based on GFP expression (Fig. 5E). Importantly, however, expression of NLRC5 
by Panc02SIY100 significantly enhanced cytotoxic cytokine secretion by 2 C cells (Fig. 5F), indicating that while 
low MHC-I expression is not a barrier to recognition of tumors by cytotoxic CD8+ T cells, upregulation of 
MHC-I on target cells by NLRC5 expression significantly improves the ability of CD8+ T cells to functionally 
respond to the antigenic stimulation. In order to test whether cancer cell upregulation of MHC-I by NLRC5 is 
sufficient to explain the increased ability of CD8+ T cells to drive tumor clearance, we generated cancer cell 
lines with constitutively high levels of MHC-I. In in vitro T cell coculture experiments, expression of NLRC5 
by Panc02SIY100 is sufficient to enhance the ability of activated 2C cells to control cancer cell growth (Fig. 5G). 
Taken together, these experiments demonstrate tight correlation between both endogenous and induced expres-
sion of NLRC5 and MHC-I expression in murine pancreatic cancer cell lines and in human patients and indi-
cate that increased expression of NLRC5, as induced by irradiation, is sufficient to enhance cytotoxic activity by 
antigen-specific CD8+ T cells in response to antigenic stimulation by cancer cells.
Discussion
Downregulation of major histocompatibility complex class I (MHC-I) molecules on cancer cells represents a 
major immune evasion tactic of murine and human cancers31–34 and, accordingly, enhancement of MHC-I status 
has been identified as a key target for effective immunotherapy35–37. In the present study we have demonstrated 
that radiation increases MHC-I expression on cancer cell surfaces, enhances susceptibility of normally resistant 
cancer cells to control by antigen-specific CD8+ T cells and identified a novel mechanism of MHC-I regulation 
by induction of NLRC5 gene expression.
Differential responses of CD8+ T cells to varying pMHC (peptide-MHC complex) concentration have 
been observed previously, wherein increased epitope density corresponds with greater responsiveness to IL-2, 
enhanced proliferation and increased cytotoxic function including cytokine production38–40. This phenomenon 
is better understood in naïve T cells, where high levels of antigen presentation in combination with costimulation 
and integrin stabilization are required to generate a stable immunological synapse and to cross an activation 
threshold of T cell receptor (TCR) signaling40,41. In activated T cells, pMHC:TCR interactions at the kinapse are 
much shorter: a single pMHC complex can serially engage with rapidly internalizing TCRs and a CD8+ T cell 
can exert cytotoxic functions after engaging with as few as 1-3 pMHC complexes per target cell42,43. It is clear 
that higher concentrations of pMHC can engage more TCRs and it has been proposed that serial engagement 
of the TCR allows increased stability and enhanced signaling within the TCR/pMHC-I/CD8 molecular com-
plex39. Functionally, downregulation of MHC-I induced by viral infection can significantly attenuate the ability of 
CD8+ T cells to kill infected targets44. Interestingly, expression of the early activation marker CD69 appears to be 
independent of epitope density45, corresponding with the data presented here demonstrating equivalent expres-
sion of Nur77 by naïve T cells cultured with MHC-Ilo Panc02SIY100 versus MHC-Ihi Panc02SIY100-NLRC5. 
However, we observed improved IFNγ and TNFα production by activated CD8+ T cells cultured with MHC-Ihi 
Panc02SIY100-NLRC5 cells in line with previous observations that increased epitope density is associated with 
increased T cell functional activation. Cumulatively, these data suggest that different densities of pMHC can 
activate different thresholds in T cells for expression of early activation markers, cytolytic degranulation and 
cytotoxic cytokine release46. These experiments support the hypothesis that increased engagement of T cell recep-
tors of effector CD8+ T cells enhances cytotoxic effector functions over those with minimally engaged TCRs. 
Importantly, in growing tumors the affinity of existing T cells may be sufficient to recognize cancer cells as meas-
ured by upregulation of activation markers, but below the critical threshold for effector functions. We interpret 
these data to suggest that it may be critical for tumors to prevent any significant IFNγ secretion by tumor-specific 
T cells, since this could result in MHCI upregulation and permit a higher avidity interactions. However, we 
are studying tumors that successfully grow in immune competent mice, or have become clinically significant in 
patients, suggesting that some degree of selection has occurred in the cancer cell-host interactions to keep T cell 
activity below this threshold. This work agrees with findings that tumor downregulation of antigen presentation 
Category Criteria Number of patients
Sex
Male 19
Female 16
T stage
ND 1
1 1
2 3
3 28
4 2
N stage
0 9
1 26
M stage
0 35
1 0
Age Mean – 68StDev - 10 Total 35
Table 1. Pancreatic adenocarcinoma RNASeq patient characteristics.
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Figure 5. NLRC5 expression by tumors increases expression of MHC-I and improves tumor control by antigen-
specific CD8+ T cells. (A) RNAseq data from pancreatic adenocarcinoma patient samples correlating NLRC5 
expression with genes involved with antigen processing and presentation. (B) (i) qRT-PCR data comparing 
NLRC5 expression of untreated pancreatic cancer cell lines normalized to GAPDH expression, (ii) representative 
histogram comparing surface MHC-I expression of untreated pancreatic tumor cell lines. (C) qRT-PCR data 
comparing gene expression in Panc02SIY100 cells 72 hours following irradiation at indicated doses. (D) (i) NLRC5 
gene construct, (ii) representative histogram comparing MHC-I expression in untreated Panc02SIY100 with and 
without induced NLRC5 expression. (E) quantification of Nur77-GFP expression of 2CNur77-GFP CD8+ T cells 
24 hours after coculture with pancreatic cancer cell lines (Panc02SIYneg, Panc02SIY100, Panc02SIY100-NLRC5). 
(F) quantification of cytotoxic cytokine production by 2C cells 72 hours after coculture with pancreatic cancer cell 
lines (Panc02SIYneg, Panc02SIY100, Panc02SIY100-NLRC5). (G) growth charts of Panc02SIY100 with or without 
IFNγ pretreatment for 24 hours or Panc02SIY100-NLRC5 during coculture with in vitro activated OT-I or 2C T 
cells. Key: *p < 0.05; ***p < 0.001; ****p < 0.0001; ns = not significant.
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via MHC-I correlates with checkpoint blockade resistance in human patients36,37 and highlights that total loss of 
MHC-I is not necessary for resistance to T cells.
In this study, we propose a novel mechanism for increasing MHC-I density on cancer cell surfaces induced 
by radiation. Previous studies of MHC-I regulation by radiation have primarily focused on two distinct mecha-
nisms for induction. One mechanism has highlighted tumor-derived type I interferon (IFN-I) signaling following 
irradiation as a mechanism of MHC-I induction22. IFN-I secretion has been observed following cancer cell irra-
diation downstream of activation of cGAS/STING signaling20, but we found that MHC-I expression on cancer 
cells following irradiation was not attenuated by knockdown of the IFN-I receptor (IFNAR). Additionally, we 
observed very little expression of STING in pancreatic cell lines that upregulated MHC-I in response to radiation. 
Together, these data suggest that in these models MHC-I upregulation is not dependent on IFN-I or STING sig-
naling. Alternatively, another mechanism has proposed that RT-induced protein damage and enhanced mTOR 
signaling, as a means to facilitate damage repair responses, leads to increased abundance of intracellular peptide 
pools and enhanced MHC-I loading to the cell surface47. We found that genes involved in antigen presentation on 
MHC-I, including the MHC-I transactivator NLRC5, were upregulated following treatment, but surprisingly that 
this was not mediated via STING-mediated innate sensing leading to type I IFN signaling (data not shown). To 
our knowledge this represents a novel mechanism of MHC-I induction on cancer cells by radiation. Together with 
data showing increased cytokine release by CD8+ T cells cultured with NLRC5-expressing Panc02SIY100, these 
data support our proposal that induction of NLRC5 by radiation enhances the ability of T cells to functionally 
respond to cancer cells expressing cognate antigen allowing for tumor regression and clearance.
Our findings here concur with prior observations that tumor control by radiotherapy and checkpoint inhibi-
tors depends on pre-existing immune responses rather than by vaccination by tumor irradiation1. In preclinical 
models, implantation of cancer cells can induce CD8+ T cell priming sufficient to establish T cell memory and 
can cause spontaneous rejection of immunogenic tumors1,48–51; in models where pre-existing anti-tumor immu-
nity is not present, additional vaccination is necessary to permit tumor control by radiation and checkpoint 
inhibition52. While vaccination effects by radiation have been observed here and elsewhere11, these data suggest 
that this response is inadequate to generate sufficiently effective T cells for tumor control. The present study 
supports an alternate mechanism by which radiation allows CD8+ T cell-mediated control of tumors by genetic 
enhancement of antigen presentation via MHC-I, thus increasing the “visibility” of cancer cells to pre-existing 
antigen-matched T cells to enhance cytotoxicity. Importantly, this does not result in tumor cure without the 
addition of PD-1/PD-L1 blockade. While radiation increases MHCI, it also increases PD-L1 on cancer cells53 and 
other immune cells in the tumor environment8, simultaneously reducing the ability of T cells to become activated. 
PD-1 ligation triggers activation of the phosphatase Shp2 in T cells, which limits costimulatory signaling through 
CD2854. Shp2 dephosphorylation of CD28 therefore increases the overall threshold for T cell activation despite 
radiation-mediated increases in avidity. Thus, the combination of MHCI increase and PD-1/PD-L1 blockade act 
together to optimize T cell responses.
NLRC5 was recently described as a master regulator of MHCI expression, with a broad set of target genes 
including critical elements of the antigen processing and presentation pathway24. The effects of NLRC5 on 
MHCI is broadly comparable to the effects of CIITA as a transactivator of MHCII expression, acting through 
cis-regulatory elements in the proximal promoter25,55, and NLRC5 and CIITA represent a distinct subgroup of 
the NLR family56. Notably, while MHCI expression is highly dependent on NLRC5 in many cell types, antigen 
presenting cells are only slightly affected by loss of NLRC557. Overexpression of NLRC5 in cancer cells dramati-
cally changed their immunogenicity, associated with upregulation of critical antigen processing and presentation 
components, and improving their recognition by specific T cells58. Thus, loss of NLRC5 represents a potential 
mechanism of immune evasion in cancer cells27. It is notable that in our models NLRC5 expression is highly vari-
able between models, but is responsive to treatment with radiation therapy. Since this mechanism is independent 
of STING and IFNAR1 in the cell, it would appear to not be regulated by classical STAT1-mediated activation 
of NLRC5 expression. Recently, Burr et al. demonstrated that Polycomb Repressive Complex 2 was co-opted to 
silence MHCI expression in cancer cells in a STAT1-independent manner, and acts in part to repress NLRC559. 
Thus, it is possible that radiation may affect the epigenetic regulation of NLRC5. However, the precise mechanism 
of NLRC5 regulation by radiation remains to be determined.
The ability of radiation to modify in-field cancer cells and alleviate αPD-1/PD-L1 blockade resistance high-
lights the need for comprehensive radiotherapy approaches encompassing the bulk of disease. This perspective 
supports incorporating combination approaches into earlier stages of disease, either in oligometastatic or locally 
advanced cancer, where all sites of gross disease are encompassed by the field of radiation.
Methods
Animals and cell lines. All experiments were performed in accordance with institutional guidelines and 
regulations – animal protocols were approved by the Earle A. Chiles Research Institute IACUC (Animal Welfare 
Assurance No. A3913-01). 5–8 week old C57BL/6 mice (Stock #000664) were purchased from the Jackson 
Laboratory (Bar Harbor, ME) for use in these experiments. Nur77GFP reporter mice were kindly provided by Dr. 
Weinberg (Earle A. Chiles Research Institute, Portland, OR)17. 2C transgenic mice that express a T cell receptor 
specific for the the SIYRYYGL peptide presented on H2Kb were kindly provided by Dr. Gajewski (University 
of Chicago, Chicago, IL), bred in-house and crossed with Nur77GFP reporter mice. OT-I transgenic mice that 
express a T cell receptor specific for the SIINFEKL peptide presented on H2Kb were gifted by Dr. Redmond (Earle 
A. Chiles Research Institute). Pdx-Cre mice (Stock #014647, Jackson Laboratory) were crossed with B6.129S4-
Gt(ROSA)26Sortm3(CAG-luc)Tyj/J (Stock #009044, Jackson Laboratory) to generate Pdx-Cre+SIY+ animals. Leaky 
expression of luciferase-SIY in these mice results in thymic tolerance to the SIYRYYGL peptide1, as has been 
previously shown with mice with a lung-restricted expression of Cre recombinase60. B6.SJL-Ptprca Pepcb/BoyJ 
mice expressing CD45.1 were obtained from the Jackson Laboratory (Stock#002014) for in vivo cytoxicity assays. 
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Survival experiments were performed with 6–8 mice per group. The experiment with SIY tolerant mice was per-
formed with four animals per group.
Cell lines were cultured in RPMI-1640 (HyClone, Fisher Scientific, Hampton, NH) supplemented with 10% 
heat inactivated fetal bovine serum (Cat#10082147, Thermo Fisher Scientific, Waltham, MA), 2 mM L-glutamine 
(Cat#SH3003401, HyClone, Fisher), 10 mM HEPES (Cat#HOL06, Caisson Labs, Smithfield, UT), 100 U/mL 
penicillin-streptomycin (Cat#PSL01, Caisson), 1X non-essential amino acids (Cat#SH3023801, Fisher), 1 mM 
sodium pyruvate (Cat#PYL01, Caisson). The parental murine pancreatic adenocarcinoma cell line Panc02 was 
kindly provided by Dr. Woo (Mount Sinai School of Medicine, New York, NY). Panc02 expressing the model 
antigen SIY was kindly provided by Dr. Weishelbaum (University of Chicago, Chicago, IL), as used previously1, 
and expresses GFP-SIY in approximately 40% of cells. Panc02SIY100 was derived and expanded from a high GFP 
expressing single clone within Panc02SIY on a BD FACSAria II cell sorter. Panc02SIYneg was similarly derived 
from a low GFP expressing clone sorted from Panc02SIY on a BD FACSAria II cell sorter (Becton Dickinson, 
Franklin Lakes, NJ). PK5L1940 was generated from established spontaneous pancreatic tumors in Pdx-Cre+/−Kr
as(G12D)+/−Trp53(R172H)+/−SIY+ as previously described1.
Antibodies and reagents. Viability staining was performed in PBS using Zombie Aqua Fixable Viability 
Kit (BioLegend, San Diego, CA) for 15 minutes prior to staining with fluorescently-conjugated antibodies for 
flow cytometry. Monoclonal antibodies were used against: CD3 [17A2], CD4 [RM4-5], CD8α [53-6.7], CD11b 
[M1/70], CD25 [PC61], CD45.1 [A20], CD45.2 [104], CD69 [H1.2F3], CD90.1 [HIS51], CD274 [MIH5], 
IFNAR1 [MAR1-5A3], IFNγ [XMG1.2], H-2Kb [AF6-88.5.5.3], TNFα [MP6-XT22], F4/80 (BM8), CD11c 
(N418), CD90.2 (30-H12), MHC-II (M5/114.14.2), Ly-6C (HK1.4), CD103 (2E9), CD24 (M1/69), CD45 
(30-F11). Fluorescently-conjugated MHC-multimer complexes were used as follows: pentamer-SIYRYYGL (pSIY, 
ProImmune, Sarasota, FL) and tetramer-SIINFEKL (tOva, NIH Tetramer Core, Atlanta, GA).
Immunohistochemistry was performed on Zinc-fixed tumors embedded in paraffin preserved as described 
previously61. Five micron sections were stained with primary αCD3 (SP7, Cat#ab16669, Abcam, Burlingame, 
CA) diluted in blocking buffer, secondary goat anti-rabbit IgG conjugated to HRP (Cat #AP1879, EMD Millipore, 
Burlingame, MA), and ImmPACT DAB Peroxidase (HRP) Substrate (Cat#SK-4105, Vector Laboratories, 
Burlingame, CA). Slides were counterstained with hematoxylin 7211 (Cat#S7439-1, Cardinal Health, Dublin, 
OH). CD3 infiltration was quantified using Aperio ImageScope (Aperio, Sausalito, CA).
For in vitro stimulation of cell lines, recombinant mouse IFN-beta protein (Cat#8234-MB-101/CF, RND 
Systems, Minneapolis, MN) at a final concentration of 1 × 103 U/mL, recombinant mouse IFN-gamma pro-
tein (Cat#14-8311-63, Thermo Fisher) at a final concentration of 20 ng/mL and mammalian 2′3′-cGAMP 
(Cat#tlrl-nacga23-02, InvivoGen, San Diego, CA) at a final concentration of 25 μg/mL were used. Cancer cells 
were irradiated before plating by timed exposure to a Cs137 source in a Gammacell Elan 3000 (MDS Nordion, 
Ottawa, ON, CAN).
The in vivo cytotoxicity experiment was conducted as described previously62. Briefly, wild-type mice were 
vaccinated with LmSIY or LmOva seven days prior to injection of congenic splenocytes labelled with CFSE 
(Cat#C34554, Thermo Fisher) and pulsed with peptide (A&A Labs, San Diego, CA). Six hours later, recipient 
spleens are harvested and analyzed by flow cytometry.
Gene editing of cancer cell lines. Panc02SIY100-NLRC5 was derived from Panc02SIY100 cells trans-
fected with a plasmid harboring the sequence for hNLRC5 under the constitutive promoter eukaryotic translation 
elongation factor 1 alpha (EF-1α) (Cat#pUNO1-hNLRC5, Invivogen, San Diego, CA). Cells with constitutively 
high expression of MHC-I were isolated by cell sorting using a BD FACSAria II cell sorter.
IFNAR1 knockout Panc02SIY100 and PK5L1940 cell lines were generated using Alt-R S.p. Cas9 Nuclease 
3NLS (Cat#192528883, Integrated DNA Technologies, Coralville, IA), Alt-R CRISPR-Cas9 tracrRNA ATTO 550 
(Cat#129528884, IDT), Opti-MEM I Reduced Serum Medium (Cat#31985062, Thermo Fisher), Lipofectamine 
CRISPRMAX Cas9 Transfection Reagent (Cat#CMAX00015, Thermo Fisher Scientific, Waltham, MA) and pre-
designed Alt-R CRISPR-Cas9 crRNA guide RNAs (IFNAR1 sequence: 5′-TCAGTTACACCATACGAATC-3′). 
Three gRNAs were tested for each target and pure populations were isolated from single cells (Panc02SIY100) 
or five cells (PK5L1940) based on ability to upregulate MHC-I in response to cytokine stimulation using a BD 
FACSAria II cell sorter.
Listeria monocytogenes vaccination. ActA deleted (ΔactA) Listeria monocytogenes (Lm) strains used 
for vaccination were engineered to express SIYRYYGL peptide (LmSIY) or SIINFEKL peptide of ovalbumin 
(LmOva) cloned in frame with the ActA N-terminal fragment. Bacteria were grown in brain-heart infusion broth, 
washed twice in PBS and administered by retro-orbital injection at a dose of 1 × 107 CFU in 100 μL total volume. 
Effective vaccination was confirmed seven days later by MHC-multimer binding of peripheral blood and as pre-
viously described63.
Immunotherapy and radiation therapy of tumors. Tumors were inoculated at a dose of 5 × 106 for 
Panc02SIY tumors, 10 × 106 for Panc02SIY100 and 10 × 106 for Panc02SIY100-IFNAR1ko tumors. Tumor size 
was determined via caliper measurements of the longest length x the longest perpendicular width. Survival end-
point was defined as tumor size greater than or equal to 150 mm2 or when the mouse appeared moribund.
For in vivo experiments, 12 Gy of CT-guided radiation was administered to tumor isocenters using a Small 
Animal Research Radiation Platform (SARRP) (Xstrahl, Suwanee, GA) and Murislice software (Xstrahl), 14 days 
after tumor implantation. 250 μg per dose αPD-L1 checkpoint blockade (Cat#BE101, BioXCell, West Lebanon, 
NH) was administered intraperitoneally at day 7, 14 and 21 post tumor implantation. Therapeutic LmSIY was 
administered at day 14 following tumor challenge to coincide with radiation controls.
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Tumor analysis. For flow cytometric analysis of tumor-infiltrating cells, tumors harvested seven days 
after treatment were chopped into small fragments and dissociated in a solution of 250 U/mL collagenase IV 
(Worthington Biochemical Corporation, Lakewood, NJ) and 30 U/mL DNase (Millipore Sigma, St Louis, MO) using 
a GentleMACS tissue dissociator (Miltenyi Biotec, Auburn, CA). After 30 minutes incubation at 37 °C, the digest was 
quenched in RPMI-1640 (Cat#SH30027LS, Fisher) supplemented with 10% FBS (Cat#16000069, Thermo Fisher) 
and 2 mM EDTA (Cat#324504, Millipore Sigma) and strained through 100 μM and 40 μM cell strainers. Filtered 
cells were rinsed in cold PBS twice prior to counting and staining for analysis on a BD LSR II flow cytometer (Becton 
Dickinson). For analysis of infiltrates of wild-type versus IFNAR1ko tumors, tumors were weighed and minced into 
small fragments, then transferred into C tubes from Miltenyi Biotec containing enzyme digest mix and the tissue 
was dissociated using a GentleMACS (Miltenyi Biotech). This was followed by incubation at 37 °C for 30 min with 
agitation and enzymatic reactions were quenched using ice cold RPMI containing 10% FBS and 2 mM EDTA.
For staining, 2 × 106 cells were stained with Zombie Aqua Viability Dye from BioLegend (#423102) in PBS for 
10 min on ice, then Fc receptors were blocked with a-CD16/CD32 antibodies from BD Biosciences (2.4G2) for an 
additional 10 min. After centrifugation, the supernatant was removed and cell were stained with a surface antibody 
cocktail containing in FACS buffer (PBS, 2 mM EDTA, 2% FBS) and Brilliant Stain Buffer Plus from BD Biosciences 
(#566385) for 20 min on ice. After surface staining, cells were washed in FACS buffer and fixed for 20 min on ice with 
Fixation/Permeabilization Buffer from BD Biosciences (#554722). All samples were resuspended in FACS buffer and 
acquired on a BD Fortessa flow cytometer. Data were analyzed using FlowJo software from Tree Star, v10.5.
In vitro T cell coculture assays. Prior to coculture with cancer cells, CD8+ T cells were activated in 
vivo with Listeria vaccines or harvested as splenocytes from naïve animals and activated in vitro with αCD3ε 
(Cat#BE0001-1, BioXCell) and αCD28 (Cat#BE0015-1) at a final concentration of 10 μg/mL each. For in vitro 
activation, after 48 hours, cells were rinsed with 10% complete RPMI supplemented with β-mercaptoethanol 
(βME) (Cat#21985023, Gibco, Thermo Fisher) and replated with 60 IU/mL human recombinant IL-2 (Chiron) 
for three days. Regardless of route of activation, CD8+ T cells were purified from splenocytes using a CD8α+ T 
cell negative isolation kit (Cat#130-104-075, Miltenyi) and counted prior to coculture.
Cancer cell growth was monitored using an Incucyte (Sartorius, Goettingen, Germany) and Zoom software 
(Incucyte, Sartorius). Briefly, cancer cells were plated in the presence of cytokines or following in vitro irradiation. After 
24 hours, adherent cells were rinsed twice in 10% complete RPMI supplemented with βME. Purified CD8+ T cells from 
Lm-vaccinated animals were added to cancer cell cultures at a 100:1 effector:target ratio; T cells from transgenic 2C or 
OT-I animals were plated at 5:1. Non-adherent cells were allowed to settle for 15 minutes at room temperature prior to 
hourly tracking in the Incucyte, housed at 36.5 °C/5%CO2, until untreated cells reached confluence. In order to isolate 
cancer cells from T cells for analysis, endogenous green fluorescence was used as a proxy for cell confluence.
Cytokine production by T cells during coculture was determined after four-hour incubation with brefeldin 
A (Cat#B7450, Thermo Fisher). Non-adherent cells were harvested, surface stained and permeablized using 
BD cytofix/cytoperm fixation and permeabilization solution (Cat#554655, Becton Dickinson), then frozen at 
−80 °C overnight. The next day, cells were thawed and rinsed twice with perm/wash buffer (Cat#554723, Becton 
Dickinson) and stained for intracellular cytokines.
Immunoblotting. Briefly, cells from pancreatic cell lines were washed twice with PBS and lysed in Pierce 
RIPA Buffer (Cat#8990, Thermo) supplemented with Halt Protease and Phosphatase Inhibitor Cocktail 
100×(Cat#78440, Thermo). Protein concentrations were quantified using Pierce BCA Protein Assay Kit 
(Cat#23225, Thermo). Samples were denatured at 95 °C in XT Sample Buffer 4×(Cat#1610791, Bio-Rad, 
Hercules, CA) and loaded onto 4–12% Criterion XT Bis-Tris Protein Gels (Cat#345-0124, Bio-Rad). Proteins 
were transferred onto PVDF Transfer Membrane (Cat#88518, Thermo) and probed for STING (Cat#13647S, 
Cell Signaling Technology, Danvers, MA), IRF3 (Cat#4302S, Cell Signaling), STAT1 (Cat#9172S, Cell Signaling), 
p-STAT1 (Y701) (Cat#7649S, Cell Signaling) and GAPDH (Cat#2118S, Cell Signaling). HRP-conjugated goat 
anti-rabbit IgG (Cat#31460, Invitrogen, Carlsbad, CA) was used as a secondary antibody. Proteins were visualized 
using SuperSignal West Pico PLUS Chemiluminescent Substrate (Cat#34580, Thermo).
RNAseq of human pancreatic tumors. Analysis of patient pancreatic tumors were approved under 
Providence IRB 10-037. We restricted our analysis to adult patients (18–100 years of age) who underwent 
up-front resection for pancreatic ductal adenocarcinoma64. We excluded patients who received neoadjuvant ther-
apy or had other cancer histologies. Demographics are outlined in Table 1. RNASeq was performed on archived 
paraffin-embedded tissue specimens from 35 patients. The FFPE tissue sections were deparaffinized using 
Envirene (Hardy Diagnostics) followed by RNA extraction and purification using the Qiagen AllPrep DNA/RNA 
FFPE kit. 85 ng of input RNA was used to prepare sequencing libraries using the Illumina TruSeq RNA Exome kit. 
Sequencing of the RNA Exome libraries was performed on the Illumina HiSeq. 4000 instrument at 2 × 75 read 
paired end configuration. Transcripts were quantified using salmon-v.0.11.265.
Gene expression analyses were performed using BRB-ArrayTools developed by Dr. Richard Simon and the 
BRB-ArrayTools Development Team.
Statistics. Data was analyzed and graphed using FlowJo (Tree Star, Ashland, OR) and Prism (GraphPad 
Software, La Jolla, CA). Individual data sets were compared using Welch’s T tests. Growth curves and analysis 
across multiple groups were analyzed using ANOVA (two-way and one-way, respectively). Kaplan Meier survival 
curves were compared using log-rank tests.
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